EP2327722A3 - Gènes de mammifères impliqués dans les infections virales et suppression de tumeur - Google Patents

Gènes de mammifères impliqués dans les infections virales et suppression de tumeur Download PDF

Info

Publication number
EP2327722A3
EP2327722A3 EP10188281A EP10188281A EP2327722A3 EP 2327722 A3 EP2327722 A3 EP 2327722A3 EP 10188281 A EP10188281 A EP 10188281A EP 10188281 A EP10188281 A EP 10188281A EP 2327722 A3 EP2327722 A3 EP 2327722A3
Authority
EP
European Patent Office
Prior art keywords
viral infection
genes involved
tumor suppression
mammalian genes
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10188281A
Other languages
German (de)
English (en)
Other versions
EP2327722A2 (fr
Inventor
Donald H. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP2327722A2 publication Critical patent/EP2327722A2/fr
Publication of EP2327722A3 publication Critical patent/EP2327722A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP10188281A 2002-05-02 2003-05-02 Gènes de mammifères impliqués dans les infections virales et suppression de tumeur Withdrawn EP2327722A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37713602P 2002-05-02 2002-05-02
EP03728671A EP1572084A4 (fr) 2002-05-02 2003-05-02 Genes de mammifere impliques dans la suppression des infections virales et des tumeurs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP03728671.3 Division 2003-05-02

Publications (2)

Publication Number Publication Date
EP2327722A2 EP2327722A2 (fr) 2011-06-01
EP2327722A3 true EP2327722A3 (fr) 2012-11-28

Family

ID=31188308

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03728671A Ceased EP1572084A4 (fr) 2002-05-02 2003-05-02 Genes de mammifere impliques dans la suppression des infections virales et des tumeurs
EP10188281A Withdrawn EP2327722A3 (fr) 2002-05-02 2003-05-02 Gènes de mammifères impliqués dans les infections virales et suppression de tumeur

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP03728671A Ceased EP1572084A4 (fr) 2002-05-02 2003-05-02 Genes de mammifere impliques dans la suppression des infections virales et des tumeurs

Country Status (6)

Country Link
US (2) US7691599B2 (fr)
EP (2) EP1572084A4 (fr)
JP (2) JP2006507807A (fr)
AU (2) AU2003234445B2 (fr)
CA (1) CA2485092A1 (fr)
WO (1) WO2004010925A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070287684A1 (en) 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009079452A2 (fr) * 2007-12-14 2009-06-25 The Brigham And Women's Hospital, Inc. Traitement et prévention d'une infection par le vih
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9340584B2 (en) 2011-03-29 2016-05-17 The General Hospital Corporation Engineered thioredoxin-like fold proteins
US9359451B2 (en) 2012-05-15 2016-06-07 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
KR20160021075A (ko) * 2013-03-14 2016-02-24 글리코비아, 인크. 올리고사카라이드 조성물, 당단백질, 및 원핵생물에서의 이들의 제조 방법
US20170364630A1 (en) * 2014-12-05 2017-12-21 Vanderbilt University Identification of cellular antimicrobial drug tablets through interactome analysis
EP3262174A4 (fr) * 2015-02-23 2018-10-17 Ionis Pharmaceuticals, Inc. Composés et procédés pour augmenter l'activité antisens
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039119A1 (fr) * 1996-04-15 1997-10-23 Vanderbilt University Genes mammiferes impliques dans l'infection virale et la suppression de tumeurs
WO1999019481A2 (fr) * 1997-10-10 1999-04-22 Vanderbilt University Genes mammaliens intervenant dans l'infection virale et la neutralisation tumorale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPH07507201A (ja) 1992-03-10 1995-08-10 ザ　ガバメント　オブ　ザ　ユナイテッド　ステイツ　オブ　アメリカ，アズ　レプリゼンテッド　バイ　ザ　セクレタリー，デパートメント　オブ　ヘルス　アンド　ヒューマン　サービシーズ 可変鋳型反応

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039119A1 (fr) * 1996-04-15 1997-10-23 Vanderbilt University Genes mammiferes impliques dans l'infection virale et la suppression de tumeurs
WO1999019481A2 (fr) * 1997-10-10 1999-04-22 Vanderbilt University Genes mammaliens intervenant dans l'infection virale et la neutralisation tumorale

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 1 November 1986 (1986-11-01), "RecName: Full=Annexin A1; AltName: Full=Annexin I; AltName: Full=Annexin-1; AltName: Full=Calpactin II; AltName: Full=Calpactin-2; AltName: Full=Chromobindin-9; AltName: Full=Lipocortin I;", XP002677960, retrieved from EBI accession no. UNIPROT:P04083 Database accession no. P04083 *
DERRY M C ET AL: "Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5", JOURNAL OF GENERAL VIROLOGY 200701 GB LNKD- DOI:10.1099/VIR.0.82294-0, vol. 88, no. 1, January 2007 (2007-01-01), pages 19 - 27, XP002677961, ISSN: 0022-1317 *
ISHIKAWA A ET AL: "Characterization of glycyrrhizin-binding protein kinase from the crude membrane fraction of rat liver", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 167, no. 3, 30 March 1990 (1990-03-30), pages 876 - 882, XP024769962, ISSN: 0006-291X, [retrieved on 19900330], DOI: 10.1016/0006-291X(90)90605-M *
RUBIN DONALD H ET AL: "Cellular genetics of host susceptibility and resistance to virus infection.", CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION 2006, vol. 16, no. 2, 2006, pages 155 - 170, XP008089598, ISSN: 1045-4403 *
TAYLOR A D ET AL: "Annexin 1 (lipocortin 1) mediates the glucocorticoid inhibition of cyclic adenosine 3',5'-monophosphate-stimulated prolactin secretion", ENDOCRINOLOGY, ENDOCRINE SOCIETY, US, vol. 141, no. 6, 1 June 2000 (2000-06-01), pages 2209 - 2219, XP002367782, ISSN: 0013-7227, DOI: 10.1210/EN.141.6.2209 *

Also Published As

Publication number Publication date
JP2010011871A (ja) 2010-01-21
EP1572084A4 (fr) 2008-04-30
EP2327722A2 (fr) 2011-06-01
JP2006507807A (ja) 2006-03-09
AU2003234445B2 (en) 2009-11-26
AU2010200729A1 (en) 2010-03-18
EP1572084A2 (fr) 2005-09-14
WO2004010925A3 (fr) 2007-06-28
US20100286251A1 (en) 2010-11-11
US20070254329A1 (en) 2007-11-01
WO2004010925A2 (fr) 2004-02-05
AU2003234445A1 (en) 2004-02-16
CA2485092A1 (fr) 2004-02-05
US7691599B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
EP2327722A3 (fr) Gènes de mammifères impliqués dans les infections virales et suppression de tumeur
WO2003012058A3 (fr) Milieux et procedes pour cultiver des micro-organismes
HK1062029A1 (en) Multiplication of viruses in a cell culture
AU2003240327A1 (en) Composition and methods for obtaining nucleic acids from sputum
AU2003257013A1 (en) Methods and compositions for amplification of dna
AU2003206095A1 (en) Methods and means for amplifying nucleic acid
AU2002306484A1 (en) Over-expression of extremozyme genes in pseudomonads and closely related bacteria
AU2002214596A1 (en) Methods and compositions for nucleic acid delivery
AU2003280603A1 (en) Method of amplifying nucleic acid
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
EA200600021A1 (ru) Пиразолопиримидины
WO2005030131A3 (fr) Composes de bis-quinazoline pour le traitement des infections bacteriennes
WO2005001039A3 (fr) Production de petits arn interferents (arnsi) regulee par les ribozymes et procedes d'utilisation de ceux-ci
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
EP0914422A4 (fr) Genes mammiferes impliques dans l'infection virale et la suppression de tumeurs
AU2003205817A1 (en) Methods of nucleic acid amplification
AU1070501A (en) Quantitation of rna transcripts using genomic dna as the internal amplification competitor
AU2003252983A1 (en) Amplification of nucleic acids
AU2003236740A1 (en) Genetically modified microorganisms, plasmid and fermentation process with the presence of flocculation regulated by medium changes
WO2001064912A3 (fr) Enzymes de degradation de triazine
WO2005059101A3 (fr) Nouveau canal sodique
WO1999019481A3 (fr) Genes mammaliens intervenant dans l'infection virale et la neutralisation tumorale
WO2002062964A3 (fr) Variants d'amine oxydase ap1
AU2002354857A1 (en) Culture medium for cultivation of filamentous fungi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1572084

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/16 20060101ALI20120705BHEP

Ipc: C07K 14/47 20060101AFI20120705BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101AFI20121023BHEP

Ipc: A61K 38/16 20060101ALI20121023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201